Beijing’s New Fast-track Review For Innovative Medicines Might Be Open Only To Made-in-China Drugs

BEIJING - China's fast-track review process for certain classes of new drugs, unveiled earlier this month, marks an advance in the country's budding support for innovative medicines, but also might be open only to domestically made products, according to Chinese and American lawyers